|drug2502||Placebo multiple Wiki||1.00|
|drug3622||XC7 100 mg single Wiki||1.00|
|drug4064||urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability and pharmacokinetics (PK) of ascending doses of XC7 after single and multiple oral administration in healthy volunteers. It's planned to include sequentially 2 cohorts of 4 volunteers who will receive a single dose of XC7 (100 mg and 200 mg) or placebo (cohort ratio 3:1) and 1 cohort of 8 volunteers who will receive multiple doses of the XC7 (200 mg) or placebo during 14 days (cohort ratio 6:2).
Description: Adverse events will be classified according to CTCAE ver 4.03. Adverse events will be summarized descriptively by treatment arm. Verbatim terms will be mapped to preferred terms and organ systems using the current Medical Dictionary for Regulatory Activities version.Measure: Number of Adverse events (AEs) per treatment arm Time: Day -7 (7 days before first dose) - Day 58
Description: Area under the curve "concentration of the drug-time" from the time of administration of the drug till infinity.Measure: Pharmacokinetics of XC7 by assessing AUC0-inf Time: Day 1 - Day 4
Description: Maximum plasma concentrationMeasure: Pharmacokinetics of XC7 by assessing Cmax Time: Day 1 - Day 4
Description: Area under the curve "concentration of the drug-time" from the time of administration of the drug till the time (t) the last blood samplingMeasure: Pharmacokinetics of XC7 by assessing AUC0-t Time: Day 1 - Day 4
Description: Time to maximum drug concentration in the blood plasma administrationMeasure: Pharmacokinetics of XC7 by assessing Tmax Time: Day 1 - Day 4
Description: Terminal elimination half-lifeMeasure: Pharmacokinetics of XC7 by assessing T1/2 Time: Day 1 - Day 4
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports